Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm after subarachnoid hemorrhage and to provide neuroprotection in patients at risk of delayed cerebral ischemia following acute cerebrovascular events.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide through regulated distribution channels.

Nimotop is used in the management of cerebrovascular conditions where impaired cerebral blood flow is a concern.

- Subarachnoid hemorrhage: reduces the incidence of delayed cerebral vasospasm and associated ischemic deficits. - Acute ischemic stroke: improves cerebral perfusion and supports neuroprotective mechanisms during the early phase of injury.

Nimodipine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Flushing: warmth and redness of skin. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac event. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Thrombocytopenia: low platelet count. - Seizures: infrequent neurologic event.

When using Nimodipine, several precautions should be observed to ensure patient safety.

- Monitor blood pressure: watch for hypotensive episodes during and after infusion. - Assess hepatic function: liver impairment may alter drug metabolism. - Use cautiously in cardiac disease: patients with recent myocardial infarction or heart failure require close observation. - Avoid rapid IV administration: infuse over the recommended period to reduce cardiovascular stress. - Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in original packaging, protect from moisture and light.

Nimodipine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: can mask tachycardia that signals hypotension. - Diuretics: additive blood‑pressure lowering effect. - Antacids or calcium supplements: may alter absorption if oral formulation is used, though IV route minimizes this.